Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Nyxoah

Financiado

Cerrado

Ultra small implanted neurostimulation device for the treatment of Obstructive S...

Ultra small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea Obstructive Sleep Apnea is the world's most common sleep disorder and affects 100m people worldwide. It is particularly prevalent among elderly and obese cohorts and is a lifelong disease, with acute and chronic health impacts. It... ver más

30/09/2016

NYXOAH SA

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NYXOAH SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-09-30

SMEInst-06-2016-2017: Accelerating market introduction of...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NYXOAH SA

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FitSleep Fabricating Non-Invasive Temporal Interference Devices for O... 150K€ Cerrado

Therapnea Therapnea Novel Therapy to treat Obstructive Sleep Apnea ba... 71K€ Cerrado

PID2021-126734OB-C21 MONITORIZACION Y EVALUACION DE LA APNEA OBSTRUCTIVA DEL SUEÑ... 161K€ Cerrado

DESARROLLO DE UN NUEVO TIPO DE DISPOSITIVO MÉ... DESARROLLO DE UN NUEVO TIPO DE DISPOSITIVO MÉDICO CPAP PAR... 465K€ Cerrado

PressureOscillations Pressure Oscillations A New Lung Therapy Approach 128K€ Cerrado

NEUROON-MED NEUROON MED the future of at home diagnosis of sleep disor... 2M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2016-05-21
Fecha Fin: 2016-09-30

Líder del proyecto

NYXOAH SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Obstructive Sleep Apnea is the world's most common sleep disorder and affects 100m people worldwide. It is particularly prevalent among elderly and obese cohorts and is a lifelong disease, with acute and chronic health impacts. It is linked to increased cardiovascular morbidity and mortality, and associated with increased risk of heart attack, cardiac arrhythmia, stroke, daytime sleepiness, depression and poor neurocognitive performance. Estimated annual economic costs of the disease are €60-150b. Established therapeutic options are uncomfortable with unpleasant side effects and/or ineffective; they can also require invasive surgery. Compliance is a major problem with the first line treatment, CPAP: 50% of users refuse it outright or fail to continue use after 1 year. Nyxoah's disruptive neurostimulation device responds directly to these needs and drawbacks. Central to the system is a tiny device implanted under the chin that - compared to other neurostimulator implantations - is smaller, less invasive and has lower risk of infection. The device is powered wirelessly by an activation chip, which is attached to a disposable smart patch and stuck under the chin before sleep. No mask, no noisy machine, no unpleasant side effects. The chip has a closed feedback loop with the implant, which detects tissue resistance and tells the chip to adjust the pulse to keep constant pressure on the nerve, to avoid burnout; it also communicates wirelessly with an app, which displays useful information (synced with the cloud) for use by patients, physicians and social security agencies; this is a key development to allow treatment compliance monitoring and therefore for reimbursement. During the Phase 1 project, the company, founded in 2009, will assess scale-up industrialization plan, product development according to regualatory standards and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores